Editas Medicine, Inc. develops genome editing medicines using CRISPR systems for serious diseases. Company news centers on its in vivo pipeline, including EDIT-401, an LDLR-targeted development candidate designed to treat hyperlipidemia by increasing LDLR protein expression and reducing LDL cholesterol.
Recurring updates include quarterly financial results, business highlights, scientific conference presentations, preclinical data for EDIT-401, intellectual property developments involving CRISPR/Cas9 patent interference, and investor conference participation. The company also reports on pipeline prioritization and its licensed Cas12a and Cas9 patent estates for human medicines.
Editas Medicine has regained full control of ocular medicines with a new agreement with AbbVie. The company is on track to dose patients in the BRILLIANCE trial for EDIT-101 by the end of 2020, and plans to file an IND for EDIT-301 for sickle cell disease. A recent equity offering raised $216 million, strengthening its balance sheet, which now holds $599 million in cash as of June 30, 2020. The company reported a net loss of $23.6 million for Q2 2020, an improvement from $33.8 million in Q2 2019, with an increase in collaboration revenues to $10.7 million.
Editas Medicine has regained full global rights to develop and commercialize ocular medicines, including EDIT-101 for Leber congenital amaurosis 10, after terminating a previous alliance with Allergan, now part of AbbVie. CEO Cynthia Collins expressed optimism about advancing EDIT-101, with dosing resuming in the Phase 1/2 BRILLIANCE trial. They aim to complete dosing of the adult low-dose cohort and dose adult mid-dose patients by year-end. J.P. Morgan Securities LLC is advising Editas on this transition.
Editas Medicine (Nasdaq: EDIT) has partnered with Catalent to enhance the development and manufacturing of its in vivo CRISPR medicines and engineered cell therapies. Catalent will support Editas with clinical supply and production from its facilities in Maryland and Texas, ensuring efficient delivery to clinical trial sites. This collaboration aims to leverage Catalent's advanced technologies to expedite Editas' innovative therapies, potentially improving patient access to new treatments.
Editas Medicine has appointed Gad Berdugo as the new Chief Business Officer, effective immediately. Berdugo brings over 25 years of experience in biotech corporate development and business strategy. He previously held executive roles at EpiVax Oncology and Immune Pharmaceuticals. Under his leadership, Editas aims to enhance its business development and advance its clinical and preclinical pipeline, which includes ongoing trials and strategic partnerships. President Cynthia Collins expressed confidence in Berdugo's ability to drive the company’s growth amidst the dynamic gene editing landscape.
Editas Medicine, a leader in genome editing, will host a conference call on August 6, 2020, at 5:00 p.m. ET to discuss its corporate updates and Q2 2020 results. Participants can join the call by dialing 844-348-3801 (domestic) or 213-358-0955 (international) and using passcode 9185596. A live webcast will also be available on their website. Editas focuses on leveraging CRISPR technology to develop transformative genomic treatments for serious diseases worldwide.
On June 26, 2020, Editas Medicine (Nasdaq: EDIT) announced the completion of its underwritten public offering, selling 6,900,000 shares of common stock at a price of $31.25 per share. The offering generated approximately $215.6 million in gross proceeds, which includes 900,000 shares sold due to underwriter options. The registration statement related to the offering has been filed and is effective with the SEC. Morgan Stanley acted as the sole book-running manager for this offering.
Editas Medicine has announced an underwritten offering of 6,000,000 shares of its common stock at a price of $31.25 per share, aiming for gross proceeds of approximately $187.5 million. The offering features a 30-day option for underwriters to purchase an additional 900,000 shares. Scheduled to close around June 26, 2020, this transaction is being managed by Morgan Stanley and follows a Form S-3 registration with the SEC.
Editas Medicine (Nasdaq: EDIT) announced plans to offer 4,000,000 shares of common stock in a public offering, with the potential to sell an additional 600,000 shares. The offering will be managed by Morgan Stanley and is subject to market conditions. A registration statement has been filed with the SEC, and the offering details will be available through the final prospectus. Editas aims to utilize the funds to advance its CRISPR-based therapeutic pipeline targeting serious diseases. The offering carries uncertainties regarding completion and final terms.
Editas Medicine (Nasdaq: EDIT) announced promising results from a pre-clinical study of EDIT-301, a gene therapy aimed at treating sickle cell disease. The study showcased a high editing efficiency of approximately 90% in both in vitro and in vivo settings. Additionally, red blood cells derived from EDIT-301 demonstrated over 50% fetal hemoglobin (HbF) expression and significant improvements in cell deformability, indicating potential clinical benefits. The company aims to file an IND for EDIT-301 by the year's end, marking a pivotal step in its development.
Editas Medicine (Nasdaq: EDIT) announced results from a pre-clinical study showcasing the efficacy of its engineered CRISPR-Cas12a technology in iPSC-derived natural killer (iNK) cells for treating solid tumor cancers. The study, presented virtually at the 23rd ASGCT Annual Meeting, demonstrated that edited iNK cells exhibited enhanced tumor-killing activity compared to unedited counterparts. Editas is advancing its oncology programs, including IND-enabling studies for its HDNK engineered cell medicine and collaborations for T cell therapies.